

Fig. 1 (for Shvedova et al.). Morphological alterations and tumor promotion in skin of SENCAR mice treated with DMBA/TPA (a) or DMBA/Cum-OOH (b) (20 weeks); insert, DMBA/acetone (magnification ×4). c) Incidence of tumors in SENCAR mice treated with DMBA/Cum-OOH or DMBA/TPA: *1*, *2*) percentage of animals having one or more papillomas induced by TPA (*1*) and Cum-OOH (*2*); *3*) percentage of animals having one or more Cum-OOH-induced carcinomas. d) Number of tumors in SENCAR mice treated with DMBA/TPA and DMBA/Cum-OOH: *1*, *2*) number of papillomas per mouse induced by TPA (*1*) and Cum-OOH (*2*); *3*) number of Cum-OOH-induced carcinomas per mouse. Values are means of 12 mice per group.




Fig. 2 (for Bagchi et al.). Hemangioma mass, incidence, and appearance. Data collected one week after subcutaneous injection of OptiBerry-treated (2) or untreated (control) EOMA cells (1) to 129P3/J mice. Data present mean \pm SD of three experiments; * lower mass compared to control group (p < 0.01). Bar graph represents the average mass of hemangioma. Scale, 1 inch.